+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07149714

Safety and Effectiveness of the iVAC 2L Transaortic Device for Temporary Mechanical Circulatory Support During High-risk Percutaneous Coronary Intervention in Adults

Led by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Updated on 2025-09-08

100

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the safety and effectiveness of the iVAC 2L transaortic device, a temporary mechanical circulatory support MCS system, in patients with coronary artery disease undergoing high-risk percutaneous coronary intervention PCI. This procedure aims to stabilize heart function during PCI, especially in patients at risk of sudden circulatory collapse. The study focuses on outcomes such as death, heart attack, stroke, and transient ischemic attack during hospitalization and up to one year after the procedure. The iVAC 2L device includes an external membrane pump and a catheter inserted through the femoral artery into the left ventricle and ascending aorta. It works in sync with the heart cycle to assist blood flow by drawing blood during heart contraction and pushing it into the aorta during relaxation. The device is minimally invasive and designed to reduce complications compared to other mechanical support options. Patients will have the device placed before or during PCI and will be closely monitored throughout the procedure and afterward. Participants will have initial assessments including ECG, echocardiography, and blood tests to evaluate heart function and overall health. After device placement and PCI, patients will be observed in the intensive care unit and receive standard medical care during hospitalization. Researchers will track various safety and effectiveness outcomes, including heart function, vascular complications, and incidents of heart attack or stroke, with follow-up continuing for 360 days after the procedure.

CONDITIONS

Brief Title

Temporary MCS With the iVAC 2L Transaortic Device in High-risk PCI

Research Team

O

Oleg Dorogun, MD

E

Eric Avetisyan, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here